Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

A CEP290 C-Terminal Domain Complements the Mutant CEP290 of Rd16 Mice In Trans and Rescues Retinal Degeneration.

Mookherjee S, Chen HY, Isgrig K, Yu W, Hiriyanna S, Levron R, Li T, Colosi P, Chien W, Swaroop A, Wu Z.

Cell Rep. 2018 Oct 16;25(3):611-623.e6. doi: 10.1016/j.celrep.2018.09.043.

2.

Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery.

Cukras C, Wiley HE, Jeffrey BG, Sen HN, Turriff A, Zeng Y, Vijayasarathy C, Marangoni D, Ziccardi L, Kjellstrom S, Park TK, Hiriyanna S, Wright JF, Colosi P, Wu Z, Bush RA, Wei LL, Sieving PA.

Mol Ther. 2018 Sep 5;26(9):2282-2294. doi: 10.1016/j.ymthe.2018.05.025. Epub 2018 Jul 7.

PMID:
30196853
3.

Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.

Bunting S, Zhang L, Xie L, Bullens S, Mahimkar R, Fong S, Sandza K, Harmon D, Yates B, Handyside B, Sihn CR, Galicia N, Tsuruda L, O'Neill CA, Bagri A, Colosi P, Long S, Vehar G, Carter B.

Mol Ther. 2018 Feb 7;26(2):496-509. doi: 10.1016/j.ymthe.2017.12.009. Epub 2017 Dec 14.

4.

Soluble FLT1 Gene Therapy Alleviates Brain Arteriovenous Malformation Severity.

Zhu W, Shen F, Mao L, Zhan L, Kang S, Sun Z, Nelson J, Zhang R, Zou D, McDougall CM, Lawton MT, Vu TH, Wu Z, Scaria A, Colosi P, Forsayeth J, Su H.

Stroke. 2017 May;48(5):1420-1423. doi: 10.1161/STROKEAHA.116.015713. Epub 2017 Mar 21.

5.

Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice.

Marangoni D, Bush RA, Zeng Y, Wei LL, Ziccardi L, Vijayasarathy C, Bartoe JT, Palyada K, Santos M, Hiriyanna S, Wu Z, Colosi P, Sieving PA.

Mol Ther Methods Clin Dev. 2016 Mar 16;5:16011. doi: 10.1038/mtm.2016.11. eCollection 2016.

6.

Preclinical Dose-Escalation Study of Intravitreal AAV-RS1 Gene Therapy in a Mouse Model of X-linked Retinoschisis: Dose-Dependent Expression and Improved Retinal Structure and Function.

Bush RA, Zeng Y, Colosi P, Kjellstrom S, Hiriyanna S, Vijayasarathy C, Santos M, Li J, Wu Z, Sieving PA.

Hum Gene Ther. 2016 May;27(5):376-89. doi: 10.1089/hum.2015.142.

7.

Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1.

Díaz-Lezama N, Wu Z, Adán-Castro E, Arnold E, Vázquez-Membrillo M, Arredondo-Zamarripa D, Ledesma-Colunga MG, Moreno-Carranza B, Martinez de la Escalera G, Colosi P, Clapp C.

Lab Invest. 2016 Mar;96(3):283-95. doi: 10.1038/labinvest.2015.135. Epub 2015 Nov 16.

8.

Long-term rescue of cone photoreceptor degeneration in retinitis pigmentosa 2 (RP2)-knockout mice by gene replacement therapy.

Mookherjee S, Hiriyanna S, Kaneshiro K, Li L, Li Y, Li W, Qian H, Li T, Khanna H, Colosi P, Swaroop A, Wu Z.

Hum Mol Genet. 2015 Nov 15;24(22):6446-58. doi: 10.1093/hmg/ddv354. Epub 2015 Sep 10.

9.

Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1.

Shen F, Mao L, Zhu W, Lawton MT, Pechan P, Colosi P, Wu Z, Scaria A, Su H.

Gene Ther. 2015 Nov;22(11):893-900. doi: 10.1038/gt.2015.57. Epub 2015 Jun 19.

10.

A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration.

Wu Z, Hiriyanna S, Qian H, Mookherjee S, Campos MM, Gao C, Fariss R, Sieving PA, Li T, Colosi P, Swaroop A.

Hum Mol Genet. 2015 Jul 15;24(14):3956-70. doi: 10.1093/hmg/ddv134. Epub 2015 Apr 15.

11.

Bill of rights for children.

Colosi PJ, Williams WV.

Linacre Q. 2014 Nov;81(4):298-301. doi: 10.1179/0024363914Z.00000000093. No abstract available.

12.

Preclinical safety evaluation of a recombinant AAV8 vector for X-linked retinoschisis after intravitreal administration in rabbits.

Marangoni D, Wu Z, Wiley HE, Zeiss CJ, Vijayasarathy C, Zeng Y, Hiriyanna S, Bush RA, Wei LL, Colosi P, Sieving PA.

Hum Gene Ther Clin Dev. 2014 Dec;25(4):202-11. doi: 10.1089/humc.2014.067.

13.

Protective effects of trehalose on the corneal epithelial cells.

Aragona P, Colosi P, Rania L, Colosi F, Pisani A, Puzzolo D, Micali A.

ScientificWorldJournal. 2014;2014:717835. doi: 10.1155/2014/717835. Epub 2014 Jun 18.

14.

Laser photocoagulation enhances adeno-associated viral vector transduction of mouse retina.

Lee SH, Colosi P, Lee H, Ohn YH, Kim SW, Kwak HW, Park TK.

Hum Gene Ther Methods. 2014 Feb;25(1):83-91. doi: 10.1089/hgtb.2013.089. Epub 2013 Dec 28.

15.

Rd9 is a naturally occurring mouse model of a common form of retinitis pigmentosa caused by mutations in RPGR-ORF15.

Thompson DA, Khan NW, Othman MI, Chang B, Jia L, Grahek G, Wu Z, Hiriyanna S, Nellissery J, Li T, Khanna H, Colosi P, Swaroop A, Heckenlively JR.

PLoS One. 2012;7(5):e35865. doi: 10.1371/journal.pone.0035865. Epub 2012 May 1.

16.

Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability.

Ramírez M, Wu Z, Moreno-Carranza B, Jeziorski MC, Arnold E, Díaz-Lezama N, Martínez de la Escalera G, Colosi P, Clapp C.

Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):8944-50. doi: 10.1167/iovs.11-8190.

PMID:
22003113
17.

PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets.

Hou X, Kumar A, Lee C, Wang B, Arjunan P, Dong L, Maminishkis A, Tang Z, Li Y, Zhang F, Zhang SZ, Wardega P, Chakrabarty S, Liu B, Wu Z, Colosi P, Fariss RN, Lennartsson J, Nussenblatt R, Gutkind JS, Cao Y, Li X.

Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12216-21. doi: 10.1073/pnas.1004143107. Epub 2010 Jun 21.

18.

Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3beta phosphorylation.

Kumar A, Hou X, Lee C, Li Y, Maminishkis A, Tang Z, Zhang F, Langer HF, Arjunan P, Dong L, Wu Z, Zhu LY, Wang L, Min W, Colosi P, Chavakis T, Li X.

J Biol Chem. 2010 May 14;285(20):15500-10. doi: 10.1074/jbc.M110.113787. Epub 2010 Mar 15.

19.

Effect of genome size on AAV vector packaging.

Wu Z, Yang H, Colosi P.

Mol Ther. 2010 Jan;18(1):80-6. doi: 10.1038/mt.2009.255. Epub 2009 Nov 10.

20.

One year outcome of manual alcohol-assisted removal of Salzmann's nodular degeneration.

Roszkowska AM, Colosi P, De Grazia L, Mirabelli E, Romeo G.

Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1431-4. doi: 10.1007/s00417-009-1154-y. Epub 2009 Aug 6.

PMID:
19657667
21.

Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse.

Park TK, Wu Z, Kjellstrom S, Zeng Y, Bush RA, Sieving PA, Colosi P.

Gene Ther. 2009 Jul;16(7):916-26. doi: 10.1038/gt.2009.61. Epub 2009 May 21. Erratum in: Gene Ther. 2009 Jul;16(7):941.

22.

Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo.

Palomeque J, Chemaly ER, Colosi P, Wellman JA, Zhou S, Del Monte F, Hajjar RJ.

Gene Ther. 2007 Jul;14(13):989-97. Epub 2007 Jan 25. Erratum in: Gene Ther. 2007 Jul;14(13):1055.

PMID:
17251988
23.

Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography.

Qu G, Bahr-Davidson J, Prado J, Tai A, Cataniag F, McDonnell J, Zhou J, Hauck B, Luna J, Sommer JM, Smith P, Zhou S, Colosi P, High KA, Pierce GF, Wright JF.

J Virol Methods. 2007 Mar;140(1-2):183-92. Epub 2006 Dec 28.

PMID:
17196264
24.

Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5.

Lochrie MA, Tatsuno GP, Arbetman AE, Jones K, Pater C, Smith PH, McDonnell JW, Zhou SZ, Kachi S, Kachi M, Campochiaro PA, Pierce GF, Colosi P.

Virology. 2006 Sep 15;353(1):68-82. Epub 2006 Jun 30.

25.

Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.

Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R, Pierce GF, Colosi P.

J Virol. 2006 Jan;80(2):821-34.

26.

Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties.

Arbetman AE, Lochrie M, Zhou S, Wellman J, Scallan C, Doroudchi MM, Randlev B, Patarroyo-White S, Liu T, Smith P, Lehmkuhl H, Hobbs LA, Pierce GF, Colosi P.

J Virol. 2005 Dec;79(24):15238-45.

27.

Identification of mouse AAV capsid-specific CD8+ T cell epitopes.

Sabatino DE, Mingozzi F, Hui DJ, Chen H, Colosi P, Ertl HC, High KA.

Mol Ther. 2005 Dec;12(6):1023-33. Epub 2005 Nov 2.

28.

Age-related modifications of the corneal endothelium in adults.

Roszkowska AM, Colosi P, D'Angelo P, Ferreri G.

Int Ophthalmol. 2004 May;25(3):163-6.

PMID:
15847315
29.

Age-related modifications of corneal sensitivity.

Roszkowska AM, Colosi P, Ferreri FM, Galasso S.

Ophthalmologica. 2004 Sep-Oct;218(5):350-5.

PMID:
15334017
30.

The adenovirus E1A and E1B19K genes provide a helper function for transfection-based adeno-associated virus vector production.

Matsushita T, Okada T, Inaba T, Mizukami H, Ozawa K, Colosi P.

J Gen Virol. 2004 Aug;85(Pt 8):2209-14.

PMID:
15269360
31.

Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.

Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S, Matsushita T, Allen J, Surosky R, Lochrie M, Meuse L, McClelland A, Colosi P, Kay MA.

Blood. 2003 Oct 1;102(7):2412-9. Epub 2003 Jun 5.

32.
33.

Distribution of AAV-TK following intracranial convection-enhanced delivery into rats.

Cunningham J, Oiwa Y, Nagy D, Podsakoff G, Colosi P, Bankiewicz KS.

Cell Transplant. 2000 Sep-Oct;9(5):585-94.

PMID:
11144956
34.

Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein.

Burton M, Nakai H, Colosi P, Cunningham J, Mitchell R, Couto L.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12725-30.

35.

Corneal endothelium evaluation in type I and type II diabetes mellitus.

Roszkowska AM, Tringali CG, Colosi P, Squeri CA, Ferreri G.

Ophthalmologica. 1999;213(4):258-61.

PMID:
10420110
36.

Efficient production of adeno-associated virus vectors using split-type helper plasmids.

Ogasawara Y, Urabe M, Kogure K, Kume A, Colosi P, Kurtzman GJ, Ozawa K.

Jpn J Cancer Res. 1999 Apr;90(4):476-83.

37.

Adeno-associated virus vectors can be efficiently produced without helper virus.

Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y, Colosi P.

Gene Ther. 1998 Jul;5(7):938-45.

38.

Efficient gene transfer into cardiac myocytes using adeno-associated virus (AAV) vectors.

Maeda Y, Ikeda U, Shimpo M, Ueno S, Ogasawara Y, Urabe M, Kume A, Takizawa T, Saito T, Colosi P, Kurtzman G, Shimada K, Ozawa K.

J Mol Cell Cardiol. 1998 Jul;30(7):1341-8.

PMID:
9710802
39.

Adeno-associated virus vector mediated transduction of primary normal human breast epithelial cells.

Yang J, Hirokawa Y, Dougherty C, Colosi P, Yang JH, Nandi S.

Oncol Rep. 1998 Jul-Aug;5(4):793-7.

PMID:
9625820
40.

Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver.

Nakai H, Herzog RW, Hagstrom JN, Walter J, Kung SH, Yang EY, Tai SJ, Iwaki Y, Kurtzman GJ, Fisher KJ, Colosi P, Couto LB, High KA.

Blood. 1998 Jun 15;91(12):4600-7.

42.

Gene transfer into vascular cells using adeno-associated virus (AAV) vectors.

Maeda Y, Ikeda U, Ogasawara Y, Urabe M, Takizawa T, Saito T, Colosi P, Kurtzman G, Shimada K, Ozawa K.

Cardiovasc Res. 1997 Sep;35(3):514-21.

PMID:
9415296
43.

Robust, but transient expression of adeno-associated virus-transduced genes during human T lymphopoiesis.

Gardner JP, Zhu H, Colosi PC, Kurtzman GJ, Scadden DT.

Blood. 1997 Dec 15;90(12):4854-64.

44.

A novel dicistronic AAV vector using a short IRES segment derived from hepatitis C virus genome.

Urabe M, Hasumi Y, Ogasawara Y, Matsushita T, Kamoshita N, Nomoto A, Colosi P, Kurtzman GJ, Tobita K, Ozawa K.

Gene. 1997 Oct 24;200(1-2):157-62.

PMID:
9373150
45.

Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.

Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ.

Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14082-7.

46.

Gene therapy against an experimental glioma using adeno-associated virus vectors.

Okada H, Miyamura K, Itoh T, Hagiwara M, Wakabayashi T, Mizuno M, Colosi P, Kurtzman G, Yoshida J.

Gene Ther. 1996 Nov;3(11):957-64.

PMID:
8940635
47.

Mutational analysis of the intracellular domain of the human growth hormone receptor.

Colosi P, Wong K, Leong SR, Wood WI.

J Biol Chem. 1993 Jun 15;268(17):12617-23.

48.

Mechanism-based design of prolactin receptor antagonists.

Fuh G, Colosi P, Wood WI, Wells JA.

J Biol Chem. 1993 Mar 15;268(8):5376-81.

49.

Mouse placental lactogen-I: RIA and gestational profile in maternal serum.

Ogren L, Southard JN, Colosi P, Linzer DI, Talamantes F.

Endocrinology. 1989 Nov;125(5):2253-7.

PMID:
2791990
50.

Cloning and expression of ovine placental lactogen.

Colosi P, Thordarson G, Hellmiss R, Singh K, Forsyth IA, Gluckman P, Wood WI.

Mol Endocrinol. 1989 Sep;3(9):1462-9.

PMID:
2608069

Supplemental Content

Loading ...
Support Center